Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Hospital Medical Center, Cincinnati | OTHER |
| Rabin Medical Center | OTHER |
| Sheba Medical Center | OTHER_GOV |
| Schneider Children's Medical Center, Israel |
Not provided
Not provided
Not provided
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) > 3,900 U/mL and ferritin >1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OHI+ patients | Adult patients with hematologic malignancies that have sCD25>3,900 U/mL and ferritin >1,000 ng/mL | ||
| OHI- patients | Adult patients with hematologic malignancies, with sCD25>3,900 U/mL and/or ferritin < 1,000 ng/mL |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To assess 365 days mortality of OHI+ and OHI- patients | The investigators will use Kaplan-Meier curves to compare survival between OHI+ and OHI- patients | Mortality rate one year from OHI assessment |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the incidence of OHI+ patients in our cohort | The investigators will assess the incidence of OHI+ within our cohort (OHI+/total patients enrolled) | The investigators will assess the incidence after three years of enrollment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male and females with new diagnosis/transformation/reactivation of hematologic malignancies
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Adi Zoref Lorenz, MD | Contact | 513 6525610 | adi.zoref.lorenz@cchmc.org | |
| Noa Rabinowicz, PhD | Contact | +972-54-4864564 | +972-9-7472398 | noa.rabinowicz@clalit.org.il |
| Name | Affiliation | Role |
|---|---|---|
| Adi Zoref-Lorenz | Meir Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Meir Medical Center | Recruiting | Kfar Saba | 4428164 | Israel |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34780598 | Background | Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, Miller PG, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Lane A, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis M, Jordan MB. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022 Feb 17;139(7):1098-1110. doi: 10.1182/blood.2021012764. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051359 | Lymphohistiocytosis, Hemophagocytic |
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D015616 | Histiocytosis, Non-Langerhans-Cell |
| D015614 | Histiocytosis |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Serum samples and peripheral blood mononuclear cells
| Rabin Medical Center | Recruiting | Petah Tikva | 49100 | Israel |
|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |